KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Q4 2025 value amounting to -$45.5 million.

  • Alnylam Pharmaceuticals' Non Operating Income rose 4880.91% to -$45.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$214.1 million, marking a year-over-year decrease of 677.54%. This contributed to the annual value of -$178.4 million for FY2025, which is 1100.5% up from last year.
  • Latest data reveals that Alnylam Pharmaceuticals reported Non Operating Income of -$45.5 million as of Q4 2025, which was up 4880.91% from -$129.0 million recorded in Q3 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Non Operating Income registered a high of $19.0 million during Q1 2021, and its lowest value of -$147.9 million during Q3 2022.
  • Over the past 5 years, Alnylam Pharmaceuticals' median Non Operating Income value was -$43.3 million (recorded in 2021), while the average stood at -$51.0 million.
  • Its Non Operating Income has fluctuated over the past 5 years, first tumbled by 58636.84% in 2022, then soared by 7564.89% in 2023.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Non Operating Income stood at -$65.7 million in 2021, then skyrocketed by 72.0% to -$18.4 million in 2022, then decreased by 15.62% to -$21.3 million in 2023, then tumbled by 317.23% to -$88.8 million in 2024, then surged by 48.81% to -$45.5 million in 2025.
  • Its last three reported values are -$45.5 million in Q4 2025, -$129.0 million for Q3 2025, and -$19.2 million during Q2 2025.